Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders.
We are focused on developing novel therapeutics that treat the underlying biological mechanisms through the MetAP2 pathway. Beloranib, our lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome and obesity caused by hypothalamic injury, including craniopharyngioma-associated obesity; and severe obesity in the general population. Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity.
We aspire to improve the lives of patients through targeted treatments and have assembled a team accomplished in bringing therapies to patients with both rare and prevalent metabolic diseases.
Zafgen has a fast-paced and collaborative culture, which drives our steadfast commitment to science and the well-being of patients. If you share our passion to improve people's lives, and thrive in a dynamic, energetic and self-motivated environment, then Zafgen may be the place for you.
